MOST VALUABLE COLLABORATION:
IBS-D Patient Engagement Platform—Allergan plc, SonarMD, Illinois Gastroenterology Group (IGG)
Limited diagnostic and therapeutic options, combined with a reluctance among patients to discuss symptoms with healthcare providers, are a major barrier to effective care for patients with IBS-D (IBS with diarrhea). Allergan collaborated with SonarMD, the developer of a cloud-based care management platform, and gastroenterologists at IGG to create an innovative engagement platform for patients with IBS-D. It has already helped to identify more than 350 IBS-D patients, over 100 of whom have enrolled.
MOST VALUABLE PATIENT INITIATIVE:
The nCompass support program provides ongoing assistance for patients as they receive Optune, an FDA-approved wearable technology for patients with glioblastoma multiforme (GBM). Optune generates low-intensity electrical fields that help slow or stop the cancer cells from dividing, and may cause some to die. A Device Support Specialist (DSS) provides training to patients and caregivers, and there is also 24/7 support. 94% of patients and caregivers rated nCompass support “excellent” or “very good.”
PATIENT ADVOCATE AWARD:
Jen Horonjeff, Savvy Cooperative
Jen is a longtime volunteer for the Arthritis Foundation and helped set up their pedsto- adult transition program, form the Young Adult Committee and establish their Patient Leadership Council. She is a patient-centered outcomes researcher at Columbia University Medical Center, where her clinical trial and treatment guidelines have been implemented in practice. Her new initiative, Savvy Cooperative, advocates for patients to be heard and for best practices in working with patients.
LIFETIME ACHIEVEMENT AWARD:
Julie L. Gerberding, MD, M.P.H. EVP, Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health, Merck & Co.
Julie Gerberding is a physician and an expert in infectious diseases. She completed her internship and residency in San Francisco in the early 80s, just as the AIDS epidemic was emerging. She later served as Director of the Centers for Disease Control and Prevention, and then joined Merck in 2010 as president of Merck Vaccines, before moving to her current position. She is also currently Adjunct Professor of Medicine in Infectious Disease at her alma mater, the University of California, San Francisco. Julie champions projects such as the HPV vaccine.